DATA SHEET - Medsafe
Changing from another combined oral contraceptive (COC), vaginal ring or transdermal patch The woman should start with Levlen ED preferably on the day after the last active
Download DATA SHEET - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION than 4 weeks …
labeling.bayerhealthcare.com3 NDA 21676 YAZ FDA Approved 09Aug2017 FULL PRESCRIBING INFORMATION WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination
A Practical Guide to Prescribing Hormone Replacement …
www.hormonebalance.orgA Practical Guide to Prescribing Hormone Replacement Therapy Karen A. McKinney and William Thompson Department of Obstetrics and Gynaecology, Queen’s University of …
Final Updated 2013 IMS Recommendations
www.imsociety.org6 Evidence of the fracture-protective effect of MHT is limited to standard dosages of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA), given by the oral route.
DATA SHEET 1. MIRENA 52 mg intrauterine contraceptive ...
www.medsafe.govt.nz180215 MIRENA DS 5 and current users of estrogen-replacement preparations should be advised of the risks and benefits of treatment and the need for treatment should be reviewed frequently.
Global Consensus Statement on Menopausal Hormone …
www.menopause.orgGlobal Consensus Statement on Menopausal Hormone Therapy de Villiers et al. 204 Climacteric breast cancer is primarily associated with the addition of
Approved Prescription Products for Menopausal …
www.menopause.org1 Approved Prescription Products for Menopausal Symptoms in the United States and Canada Oral estrogen products Revised: February 2016 (Providers should check the full prescribing information for appropriate dosages for the indication